The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk

• Main Authors: Chang Xu (Author), Xudong Gao (Author), Tianshu Ren (Author), Hefeng Geng (Author), Kaisi Yang (Author), Yaoguang Huang (Author), Weige Zhang (Author), Shanbo Hou (Author), Aigang Song (Author), Yingshi Zhang (Author), Qingchun Zhao (Author)
• Format: Book
• Published: Elsevier, 2024-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ZLDI-8 is an A disintegrin and metalloproteinase domain 17 (ADAM17) inhibitor that suppresses the shedding of Notch1 to the Notch1 intracellular domain (NICD). In previous studies, we found that ZLDI-8 was able to sensitize HCC to sorafenib, but the mechanism of action remains unclear. The sensitizi...